About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Gland Pharma Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
543245
ISIN Demat
INE068V01023
Book Value
610.02
NSE Code
GLAND
Dividend Yield %
0.97
Market Cap
306570.51
P/E
26.51
EPS
70.19
Face Value
1
BSE
NSE
07-Nov-2025
BSE
NSE
NSE F & O
07-Nov-2025
BSE
NSE
NSE F & O
Last Price
1860.75
Net Change
-37.75
% Change
-1.99%
Prev.Close
1898.50
Open
1875.55
High
1899.00
Low
1855.00
Volume
1613
Last Price
1863.00
Net Change
-35.6
% Change
-1.88%
Prev.Close
1898.60
Open
1895.00
High
1897.50
Low
1855.10
Volume
111371
Value
3017311
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
1899.00
52-Week High
2130.00
52-Week Low
1200.00
Value
207785526.2
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
1897.50
52-Week High
2131.00
52-Week Low
1277.80
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Book Closure
10-Aug-21
26-Aug-21
Dividend
1800 %
14-Aug-25
Company News
04-11-2025
Gland Pharma reports 12% ...
03-11-2025
Gland Pharma informs abou...
17-10-2025
Gland Pharma informs abou...
17-10-2025
Gland Pharma informs abo...
08-09-2025
Gland Pharma informs abou...
26-08-2025
Gland Pharma receives USF...
12-08-2025
Gland Pharma gets USFDA’s...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.
